Reactivation of hepatitis B virus infection

Also known as: Hepatitis B virus reactivation / Reactivation of hepatitis B infections / Reactivation of Hepatitis B Virus / Hepatitis B recurrence / HBV reactivation / Hepatitis B Reactivation / Serum hepatitis / Viral hepatitis B / Hep B / Hepatitis B

DrugDrug NameDrug Description
DB05276Hepatitis B Immune GlobulinLong-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine. HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
DrugDrug NameTargetType
DB05276Hepatitis B Immune GlobulinHBsAgtarget
DrugDrug NamePhaseStatusCount
DB00442Entecavir2Unknown Status1
DB00709Lamivudine2Unknown Status1
DB09102Daclatasvir2 / 3Recruiting1
DB09183Dasabuvir2 / 3Recruiting1
DB00442Entecavir2 / 3Recruiting1
DB09027Ledipasvir2 / 3Recruiting1
DB09296Ombitasvir2 / 3Recruiting1
DB09297Paritaprevir2 / 3Recruiting1
DB00503Ritonavir2 / 3Recruiting1
DB08934Sofosbuvir2 / 3Recruiting1
DB00300Tenofovir disoproxil2 / 3Recruiting1
DB00442Entecavir4Active Not Recruiting1